ATTN: As of June 9, our Harbour View office in Suffolk has relocated to 3910 Bridge Road, Ste. 400.   2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk.  Medicare Fraud Scheme Regarding Genetic Testing - Click Here

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » uso 22326

uso 22326

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-Women and Men, >18 years at the time of screening (or per national guidelines)                                                                                                                                                                              -Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol.                                                                                                                                                                                                                                                                                                  -Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy                                --Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor)                                                                                                                                          -Eastern Cooperative Oncology Group (ECOG) performance status of < 1                                                                                                                                                                                          -Adequate organ and marrow function

Available at:

Virginia Oncology Associates